A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-012
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 06 Jun 2017 Results evaluating tumor and immune cells using the combined positive score method in patient specimens for the gastric indication, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results of genomic determinants of response to pembrolizumab in patients with HPV, EBV virus infection (n=73) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 09 Jan 2017 Results (Cut off date Sept 1, 2015; n=27) assessing safety and efficacy of pembrolizumab in urothelial cancer cohort, published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top